Martin Reck, MD, PhD of LungenClinic Grosshansdorf, Grosshansdorf, Germany discusses the implication of the KEYNOTE-024 trial results for advanced lung cancer. According to Dr Reck, this data will completely change the management of patients. At diagnosis, we have to look at oncogenic alterations but now it is also important to screen patients for PD-L1 expression. Patients with high PD-L1 can be treated with pembrolizumab, which is now an option for first-line therapy for this group of patients. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.